Comparison of efficacy and safety of topical tacrolimus vs. narrowband ultraviolet B for moderate-severe atopic eczema

Authors

  • Asia Bano Department of Dermatology, Faisal Masood Teaching Hospital, Sargodha.
  • Mahwash Rana Department of Dermatology, Continental Medical College, Lahore.
  • Zareen Saqib Suleri Department of Dermatology, Government Khawaja Muhammad Safdar Medical College, Sialkot.
  • Muntaha Javed Services Institute of Medical Sciences, Lahore.
  • Nadia Sultan Department of Dermatology, Rahbar Medical and Dental College, Lahore.
  • Ghazala Butt Department of Dermatology, KEMU/ Mayo Hospital, Lahore.

DOI:

https://doi.org/10.66344/jpad.v33i2.2528

Keywords:

Atopic dermatitis; Topical tacrolimus; NB UVB

Abstract

Objective To compare the efficacy and safety of topical tacrolimus with narrowband ultraviolet B for moderate-severe atopic eczema.

 

Methods 60 subjects, equally divided into Group A and B with the former treated with topical tacrolimus and the latter received narrowband ultraviolet B (NB UVB). These patients were followed up at 2, 4, 6, 8 and 12th weeks. Efficacy and side effects of the given treatment were recorded at each visit.

 

Results 90% of patients receiving NB UVB showed ≥50% SCORAD reduction as compared to 50% of cases applying tacrolimus. Fewer patients (60%) on NB UVB had side effects as compared to 66% of tacrolimus patients.

 

Conclusion NB UVB is a more effective and safer therapy than topical tacrolimus in moderate-severe atopic dermatitis in our patients.

 

References

1. Bylund S, von Kobyletzki LB, Svalstedt M, Svensson Å. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm Venereol. 2020;100(12):320-9.

2. Raimondo A, Lembo S. Atopic dermatitis: epidemiology and clinical phenotypes. Dermatol Pract Concept. 2021;11(4): e2021146.

3. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113(5):832-6.

4. Kim J, Kim BE, Leung DY. Pathophysiology of atopic dermatitis: Clinical implications. Allergy Asthma Proc. 2019;40(2):84.

5. Laughter MR, Maymone MB, Mashayekhi S, Arents BW, Karimkhani C, Langan SM, Dellavalle RP, Flohr C. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990–2017. Br J Dermatol. 2021;184(2):304-9.

6. Plant A, Ardern-Jones MR. Advances in atopic dermatitis. Clin Med. 2021;21(3):177.

7. Chopra R, Vakharia PP, Sacotte R, Patel N, Immaneni S, White T, Kantor R, Hsu DY, Silverberg JI. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol. 2017;177(5):1316-21.

8. Wollenberg A, Christen‐Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin‐Weller M, Vestergaard C, Seneschal J, Werfel T, Cork MJ, Kunz B. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717-44.

9. Kemény L, Varga E, Novak Z. Advances in phototherapy for psoriasis and atopic dermatitis. Expert Rev Clin Immunol. 2019;15(11):1205-14.

10. Nguyen HL, Trujillo-Paez JV, Umehara Y, Yue H, Peng G, Kiatsurayanon C, Chieosilapatham P, Song P, Okumura K, Ogawa H, Ikeda S. Role of antimicrobial peptides in skin barrier repair in individuals with atopic dermatitis. Int J Mol Sci. 2020;21(20):7607.

11. Broen JC, van Laar JM. Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology. Nat Rev Rheumatol. 2020;16(3):167-78.

12. Ohtsuki M, Morimoto H, Nakagawa H. Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: review on safety and benefits. J Dermatol. 2018;45(8):936-42

13. Williams HC, Jburney PG, Hay RJ, Archer CB, Shipley MJ, Ahunter JJ, Bingham EA, Finlay AY, Pembroke AC, Cgraham‐Brown RA, Atherton DA. The UK Working Party's Diagnostic Criteria for Atopic Dermatitis. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol. 1994;131(3):383-96.

14. Chng WQ, Yew YW. 14340 Gender proportions by region and age groups in atopic dermatitis. J Am Acad Dermatol. 2020;83(6):AB136.

15. Saleem S, Shaikh ZI, Akbar N, Kausar S. Comparison of the Efficacy of Probiotics Versus Placebo in the Treatment of Atopic Dermatitis in Children. Pak Armed Forces Med J. 2022;72(5):1748-51.

16. Perälä M, Salava A, Malmberg P, Pelkonen AS, Mäkelä MJ, Remitz A. Topical tacrolimus versus corticosteroids in childhood moderate-to-severe atopic dermatitis and the impact on airway inflammation: a long-term randomized open-label study. Clin Exp Dermatol. 2023;48(6):660-6.

17. Zhao S, Hwang A, Miller C, Lio P. Safety of topical medications in the management of pediatric atopic dermatitis: an updated systematic review. Br J Clin Pharmacol. 2023;1-27. doi:10.1111/bcp.15751

18. Hong CH, Gooderham M, Bissonnette R. Evidence review of topical Calcineurin inhibitors for the treatment of adult atopic dermatitis. J Cutan Med Surg. 2019;23(4-suppl):5S-10S.

19. Reitamo S, Ortonne JP, Sand C, Bos J, Cambazard F, Bieber T, Grønhøj-Larsen C, Rustin M, Fölster-Holst R, Schuttelaar M, European Tacrolimus Ointment Study Group. Long-term treatment with 0.1% tacrolimus ointment in adults with atopic dermatitis: results of a two-year, multicentre, non-comparative study. Acta Derm Venereol. 2007;87(5):406-12.

20. Tintle S, Shemer A, Suárez-Fariñas M, Fujita H, Gilleaudeau P, Sullivan-Whalen M, Johnson-Huang L, Chiricozzi A, Cardinale I, Duan S, Bowcock A. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. J Allergy Clin Immunol. 2011;128(3):583-93.

21. Clayton TH, Clark SM, Turner D, Goulden V. The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy. Clin Exp Dermatol. 2007;32(1):28-33.

22. Tzung TY, Lin CB, Chen YH, Yang CY. Pimecrolimus and narrowband UVB as monotherapy or combination therapy in children and adolescents with atopic dermatitis. Acta Derm Venereol. 2006;86(1): 34-8.

23. Rossi M, Damiani C, Arisi M, Tomasi C, Tonon F, Venturini M, Calzavara-Pinton P. Definition of the Clinical Characteristics of Patients with Moderate and Severe Atopic Dermatitis for Whom Narrow-Band UVB (NB-UVB) and Medium-Dose UVA1 Phototherapies Are Still Valuable Treatment Options at the Age of Biologics. J Clin Med. 2023;12(9):3303.

doi: 10.3390/jcm12093303.

Downloads

Published

28.06.2023

Issue

Vol. 33 No. 2 (2023): April-June

Section

Original Articles

License

Copyright (c) 2023 Asia Bano, Mahwash Rana, Zareen Saqib Suleri, Muntaha Javed, Nadia Sultan, Ghazala Butt

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Submission declaration

Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.

By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.

How to Cite

1.
Comparison of efficacy and safety of topical tacrolimus vs. narrowband ultraviolet B for moderate-severe atopic eczema. J Pak Assoc Dermatol [Internet]. 2023 Jun. 28 [cited 2026 Aug. 2];33(2):643-7. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/2528